Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Prepaid Assets (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Prepaid Assets for 4 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 18.55% year-over-year to $10.9 million; the TTM value through Dec 2025 reached $10.9 million, down 18.55%, while the annual FY2025 figure was $10.9 million, 18.55% down from the prior year.
  • Prepaid Assets was $10.9 million for Q4 2025 at Day One Biopharmaceuticals, up from $1.3 million in the prior quarter.
  • The five-year high for Prepaid Assets was $380.5 million in Q3 2022, with the low at $384000.0 in Q1 2024.
  • Historically, Prepaid Assets has averaged $28.7 million across 4 years, with a median of $5.4 million in 2023.
  • The largest annual shift saw Prepaid Assets tumbled 97.96% in 2023 before it surged 934.9% in 2025.
  • Over 4 years, Prepaid Assets stood at $1.6 million in 2022, then soared by 460.74% to $8.9 million in 2023, then surged by 50.25% to $13.4 million in 2024, then decreased by 18.55% to $10.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Prepaid Assets were $10.9 million in Q4 2025, $1.3 million in Q3 2025, and $1.8 million in Q2 2025.